If your embryo had PGT-A before transfer, you may wonder why your pregnancy care team is offering another chromosome screening test. The reason is straightforward: PGT-A helps assess an embryo before pregnancy. Prenatal testing gives you information during pregnancy.
You can still choose prenatal screening or diagnostic testing after PGT-A. ACOG recommends that these options be offered to every pregnant patient, including those who had preimplantation genetic testing. Your next step is to discuss which information you want and how the available tests could help you get it.
What PGT-A has already told you
PGT-A screens a small sample of cells from an embryo for differences in chromosome number. A result described as euploid means the tested sample had the expected number of chromosomes within the test’s scope.
That result can help your fertility team decide which embryo to transfer. It doesn’t replace pregnancy testing, because the sample represents part of the embryo and the test doesn’t assess every possible genetic condition.
If you also had PGT-M for a specific inherited condition, bring that report to your prenatal appointment. Your care team needs to know exactly what was tested, rather than simply that your embryo had “genetic testing.”
What NIPT adds during pregnancy
Noninvasive prenatal testing, also called cell-free DNA screening, uses a blood sample from the pregnant person. It examines DNA fragments that mainly come from the placenta to estimate the chance of certain chromosome conditions.
NIPT is commonly available from about 10 weeks of pregnancy. The exact conditions covered depend on the test. It is a screening test: a higher-chance result needs diagnostic testing to establish whether the pregnancy is affected.
You don’t have to choose the largest panel to make a useful decision. Ask which conditions the proposed test screens for, how reliable it is for those conditions, and what a result would change for you.
Screening and diagnosis answer different questions
Screening estimates the chance of a condition. Diagnostic testing examines cells obtained through procedures such as chorionic villus sampling, or CVS, and amniocentesis.
CVS samples placental tissue. Amniocentesis samples fluid containing fetal cells. They happen at different stages and carry considerations your pregnancy care team can explain. If you want a diagnostic answer about a condition previously assessed with PGT-M or PGT-SR, ask what testing would be needed to address that specific result.
A useful question is: “Would this test give us a risk estimate or a diagnosis, and what would we do after either result?”
Bring your embryo report to your first appointment
Share your PGT-A report and any PGT-M, PGT-SR, or other genetic reports with the clinician managing your pregnancy. Mention donor eggs or sperm, a known family condition, or a previous result that needed interpretation.
You can then decide together whether to have NIPT, another screening approach, diagnostic testing, or no genetic testing. Your preferences matter. Ultrasound and routine pregnancy care remain important whichever genetic testing option you choose.
For more detail, see ACOG’s guidance on preimplantation genetic testing and its explanation of prenatal genetic screening tests.
If you have a Nucleus Embryo report, the genetic counseling included with Embryo can help you understand what that report says. Your pregnancy care team can then help you choose the prenatal testing that fits your situation.




